Provision of SCID Screening Assay Kits

NHS England has successfully completed the procurement process for the provision of SCID Screening Assay Kits under the National Microbiology Framework, utilising a selective procurement method as a call-off from a framework agreement. The procurement was valued at £310,000 and was awarded to Revvity (UK) Limited. This service-focused contract pertains to the health services industry category and was particularly aimed at supporting the NHS Newborn Blood Spot (NBS) evaluation for Severe Combined Immuno-Deficiency (SCID) in screening laboratories.

The procurement stage in question is the award stage, with the contract period having commenced on 1st April 2025 and set to conclude on 30th September 2025. The tender activities were connected to NHS England's base in Leeds, and the project location is denoted as England, UK. Key parties involved included buyer NHS England and supplier Revvity (UK) Limited.

This procurement presents significant opportunities for businesses specialising in health services to engage with large healthcare frameworks. Suppliers with expertise in health services, particularly those familiar with neonatal screening requirements, will find this tender beneficial for growth and development. As the procurement encouraged participation from SMEs and voluntary, community, and social enterprises (VCSEs), businesses in these categories can take advantage of similar opportunities in the future to broaden their market presence.

Successful engagement in such contracts not only enhances business credibility but also fosters valuable relationships with prominent healthcare institutions like NHS England.